Viewing data from:

REYVOW

NDA

LASMIDITAN SUCCINATE | N211280 | ELI LILLY AND CO

3 strengths4 unique patents0 unique exclusivities

Patent Timeline

4 unique patents by expiration date

Active (4)Today

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

2040

2041

Today

Feb. 17, 2028

Dec. 5, 2037

Jul. 6, 2040

Jul. 7, 2030

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

4 cases on OB patents from PACER

Case	Court	Filed	Status	Judge
ELI LILLY & COMPANY et al v. QILU PHARMACEUTICAL CO., LTD. et al 2:2026cv02866 1 patentANDA 219350lasmiditan	D.N.J.	2026-03-19	Terminated 2026-04-02	—
ELI LILLY & COMPANY et al v. QILU PHARMACEUTICAL CO., LTD. et al 2:2025cv12347 1 patentANDA 219350lasmiditan	D.N.J.	2025-06-30	Terminated 2025-07-08	—
Eli Lilly & Company et al v. Humanwell Pharmaceutical US, Inc. et al 4:2025cv00362 1 patentANDA 219669lasmiditan	E.D. Mo.	2025-03-21	Terminated 2025-07-07	—
ELI LILLY & COMPANY et al v. HUMANWELL PHARMACEUTICAL US, INC. et al 2:2025cv02020 1 patentANDA 219669lasmiditan	D.N.J.	2025-03-21	Terminated 2025-10-08	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

8 trials from ClinicalTrials.gov, 8 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users NCT03286218	Phase 1	Completed	Eli Lilly and Company	96	2017-09-15 → 2017-11-20
A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants NCT03310411	Phase 1	Completed	Eli Lilly and Company	40	2017-10-17 → 2017-12-23
A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants NCT03459612	Phase 1	Completed	Eli Lilly and Company	68	2018-03-26 → 2018-06-23
A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate NCT03308669	Phase 1	Completed	Eli Lilly and Company	30	2017-10-16 → 2017-12-02
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants NCT03012334	Phase 1	Completed	Eli Lilly and Company	90	2017-01-16 → 2017-06-08
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants NCT03076970	Phase 1	Completed	Eli Lilly and Company	42	2017-03-21 → 2017-04-13
A Study of Lasmiditan and Propranolol in Healthy Participants NCT03270644	Phase 1	Completed	Eli Lilly and Company	44	2017-08-31 → 2017-11-22
A Study of Lasmiditan on the Heart in Healthy Participants NCT03465436	Phase 1	Completed	Eli Lilly and Company	56	2011-09-16 → 2011-12-20

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$88.77

per ea

Lowest NADAC/Unit

$88.70

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00002449108REYVOW 100 MG TABLET	$88.77	EA	Brand	—	2026-05-20
00002431208REYVOW 50 MG TABLET	$88.70	EA	Brand	—	2026-05-20

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 4 NDCs (2 FSS, 2 Big4)

Lowest Price

$552.95

Highest Price

$691.14

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00002-4312-08REYVOW 50MG TAB	$691.14	FSS	Eli Lilly & Company	09/28/2030
00002-4312-08REYVOW 50MG TAB	$552.95	Big4	Eli Lilly & Company	09/28/2030
00002-4491-08REYVOW 100MG TAB	$691.14	FSS	Eli Lilly & Company	09/28/2030
00002-4491-08REYVOW 100MG TAB	$553.78	Big4	Eli Lilly & Company	09/28/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Reyvow (2024)

Total Spending

$9.8M

Total Claims

11,829

Beneficiaries

3,067

Avg Cost/Unit

$91.20

Spending Trend

$2.5M(2020)→$5.8M(2021)→$8.3M(2022)→$9.9M(2023)→$9.8M(2024)

YoY Change:-6.7%

5yr CAGR:+2.7%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Approval Letters

6 letters from Drugs@FDA

Date	Submission	Document
Sep 16, 2022	SUPPL -8	View Letter (PDF)
Jul 18, 2022	SUPPL -7	View Letter (PDF)
Jan 28, 2022	SUPPL -6	View Letter (PDF)
Jun 7, 2021	SUPPL -5	View Letter (PDF)
Jul 20, 2020	SUPPL -1	View Letter (PDF)
Feb 19, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (3)

Sort:

#001 — EQ 50MG BASE

RLD

4 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 31, 2020

Patents (4) · 3 use codes

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
7423050	Feb 17, 2028	—	Yes	Yes		—
11053214	Dec 5, 2037	—	Yes	Yes		—
12071423	Jul 6, 2040	—	—	Yes	—	—
12257246	Jul 7, 2030	—	—	—		—

#002 — EQ 100MG BASE

RLD

4 patents0 exclusivities▾

TABLET;ORAL | Approved: Jan 31, 2020

#003 — EQ 200MG BASE

RLD

3 patents0 exclusivities▾

TABLET;ORAL | Approved: Dec 18, 2020